Registration for this event is now closed. If you'd like to attend, please contact Philippa Clark on [email protected]
 

In association with: 

Progress towards early development value inflection points is critical to a life science company’s ability to re-finance or secure sought after R&D deals and licensing with Pharma. Australia, with streamlined approval processes and clear R&D tax credit policies has developed an enviable track record of helping companies traverse early development challenges in a timely and cost-effective manner. One Nucleus is keen to ensure our respective members are able to make informed choices about their routes to growth and are delighted to be hosting 360Biolabs and partners in bringing their insights to the UK.

At this event, delegates will learn why Australia is one of the top three destinations for outsourced early phase clinical trials (along with US and China) and why it is reported that conducting a study in AUS vs US (IND required) or EU can save a biotech 6-12 months off their clinical timeline.

Programme
09:15 – Registration with Tea/Coffee
09:30 – Welcome
09:40 – The Australia Advantage
10:40 – Close Remarks
10:45 - Close

Speakers:
Angela Luttick
EVP Commercial
360Biolabs, a BioAgilytix Company

Cheryl-Ann Hawkins
Chief Executive Officer
Veritus Research

Louise Moore
Co-Founder and Director
Beyond Drug Development

George Zafiris
Associate
Prime Accounting and Business Advisory

Prices:
Members of One Nucleus, OBN or MedCity: Free (Please email [email protected] to register if you are an OBN or MedCity member)
Non-members: £50 +VAT

If you have any questions about this event, please contact Philippa Clark on [email protected]